Lineage Cell Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Lineage Cell Therapeutics' CEO'su Brian Culley, Sep2018 tarihinde atandı, in görev süresi 6.08 yıldır. in toplam yıllık tazminatı $ 2.91M olup, şirket hissesi ve opsiyonları dahil olmak üzere 22% maaş ve 78% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.082% ine doğrudan sahiptir ve bu hisseler ₪ 528.42K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 8 yıldır.

Anahtar bilgiler

Brian Culley

İcra Kurulu Başkanı

US$2.9m

Toplam tazminat

CEO maaş yüzdesi	22.0%
CEO görev süresi	6.1yrs
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Brian Culley'un ücretlendirmesi Lineage Cell Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$24m
Mar 31 2024	n/a	n/a	-US$24m
Dec 31 2023	US$3m	US$640k	-US$21m
Sep 30 2023	n/a	n/a	-US$23m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$2m	US$609k	-US$26m
Sep 30 2022	n/a	n/a	-US$49m
Jun 30 2022	n/a	n/a	-US$51m
Mar 31 2022	n/a	n/a	-US$49m
Dec 31 2021	US$3m	US$580k	-US$43m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$1m	US$552k	-US$21m
Sep 30 2020	n/a	n/a	-US$27m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$59m
Dec 31 2019	US$773k	US$536k	-US$12m
Sep 30 2019	n/a	n/a	-US$52m
Jun 30 2019	n/a	n/a	US$31m
Mar 31 2019	n/a	n/a	US$57m
Dec 31 2018	US$3m	US$155k	-US$46m

Tazminat ve Piyasa: Brian 'nin toplam tazminatı ($USD 2.91M ), IL pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 660.96K ).

Tazminat ve Kazançlar: Brian şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Brian Culley (53 yo)

6.1yrs

Görev süresi

US$2,905,130

Tazminat

Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer, Principal Financial Officer at Lineage Cell Therapeutics, Inc. since July 8, 2022 until November 14, 2022. He served as Interim...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Brian Culley	CEO, President & Director	6.1yrs	US$2.91m	0.082% ₪ 502.6k
Jill Howe	CFO & Principal Financial and Accounting Officer	1.9yrs	US$738.86k	0.0056% ₪ 34.1k
George Samuel	General Counsel & Company Secretary	3.1yrs	US$1.21m	0.0038% ₪ 23.3k
Ioana Hone	Director of Investor Relations	no data	Veri yok	Veri yok
Charlotte Hubbert	Vice President of Corporate Development	less than a year	Veri yok	Veri yok
Brandi Roberts	Consultant	3.8yrs	US$668.25k	Veri yok
William Annett	President & CEO of OncoCyte Corporation	no data	US$654.85k	Veri yok
Rami Skaliter	Chief Executive Officer of Cell Cure Neurosciences	no data	Veri yok	Veri yok
Alexandra Hernandez	Senior Director of Finance & Controller	5.1yrs	Veri yok	Veri yok
Harold Waitz	Vice President of Regulatory Affairs & Quality Control	29.8yrs	US$90.00k	Veri yok

3.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: LCTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Brian Culley	CEO, President & Director	6.1yrs	US$2.91m	0.082% ₪ 502.6k
Don Bailey	Independent Director	5.6yrs	US$130.50k	0.084% ₪ 515.4k
Angus Russell	Independent Director	9.8yrs	US$138.00k	0.046% ₪ 284.0k
Anula Jayasuriya	Independent Director	3.4yrs	US$128.00k	0.0053% ₪ 32.5k
Neal Bradsher	Independent Director	15.3yrs	US$141.13k	0.046% ₪ 284.4k
Deborah Andrews	Independent Director	10.5yrs	US$148.00k	0.0083% ₪ 50.6k
Michael Mulroy	Independent Chairman	10yrs	US$151.13k	0.14% ₪ 839.2k
Dipti Amin	Independent Director	3.5yrs	US$128.00k	0.019% ₪ 113.6k

8.0yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LCTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8 yıldır).

Lineage Cell Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors

Lineage Cell Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Independent Director recently bought ₪370k worth of stock

Lineage Cell Therapeutics, Inc., Annual General Meeting, Sep 06, 2023

Lineage Cell Therapeutics, Inc Appoints Jill A. Howe as Chief Financial Officer, Effective November 14, 2022

Recent updates

Lineage Cell Therapeutics, Inc. Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance, at the 59th Annual Inner Ear Biology Workshop

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.031 loss per share (vs US$0.031 loss in 2Q 2023)

Lineage Cell Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Profitability

First quarter 2024 earnings released: US$0.036 loss per share (vs US$0.026 loss in 1Q 2023)

Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Insufficient new directors

Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors

Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

No longer forecast to breakeven

Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting

Full year 2023 earnings released: US$0.12 loss per share (vs US$0.15 loss in FY 2022)

Lineage Cell Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Lineage Cell Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury

Independent Director recently bought ₪370k worth of stock

Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000002 million.

Forecast to breakeven in 2026

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Third quarter 2023 earnings released: US$0.041 loss per share (vs US$0.036 loss in 3Q 2022)

Lineage Cell Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

New major risk - Share price stability

Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501

Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501

Second quarter 2023 earnings released: US$0.031 loss per share (vs US$0.04 loss in 2Q 2022)

Lineage Cell Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Lineage Cell Therapeutics and Cancer Research UK Reports Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

New minor risk - Shareholder dilution

New minor risk - Share price stability

Lineage Cell Therapeutics, Inc., Annual General Meeting, Sep 06, 2023

First quarter 2023 earnings released: US$0.026 loss per share (vs US$0.042 loss in 1Q 2022)

Lineage Cell Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.26 loss in FY 2021)

Forecast to breakeven in 2025

Lineage Cell Therapeutics, Inc. Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss

Lineage Announces Launch of Phase 2A Study by Genentech of RG6501 (OpRegen®) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Third quarter 2022 earnings released: US$0.036 loss per share (vs US$0.047 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.036 loss per share (vs US$0.047 loss in 3Q 2021)

Lineage Cell Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Lineage Cell Therapeutics, Inc Appoints Jill A. Howe as Chief Financial Officer, Effective November 14, 2022

Second quarter 2022 earnings released: US$0.04 loss per share (vs US$0.029 loss in 2Q 2021)

Lineage Cell Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Lineage Cell Therapeutics, Inc. Announces Chief Financial Officer Changes

Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) dropped from Russell 2000 Value Index

First quarter 2022 earnings released: US$0.042 loss per share (vs US$0.009 loss in 1Q 2021)

Lineage Cell Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

No longer forecast to breakeven

Lineage Cell Therapeutics, Inc. Announces A Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

Lineage Cell Therapeutics, Inc. and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of Vac2 for the Treatment of Non-Small Cell Lung Cancer

Independent Director recently bought ₪184k worth of stock

No longer forecast to breakeven

Forecast to breakeven in 2024

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Lineage Cell Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Forecast to breakeven in 2024

Insider recently sold ₪216k worth of stock

Lineage Cell Therapeutics, Inc. Reports Fourth Case of Retinal Tissue Restoration with Opregen®

Third quarter 2021 earnings released: US$0.047 loss per share (vs US$0.052 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.029 loss per share (vs US$0.044 loss in 2Q 2020)

Lineage Cell Therapeutics, Inc. Announces Updated Interim Results from Phase 1/2a Study of its Lead Product Candidate, OpRegen

Lineage Cell Therapeutics, Inc. Provides an Update on the Clinical Advancement of OPC1

Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry Amd Patients Treated with Opregen Rpe Cells

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.009 loss per share (vs US$0.056 loss in 1Q 2020)

Lineage Cell Therapeutics, Inc. Announces Updated Interim Results from Its Ongoing, 24-Patient Phase 1/2A Clinical Study of Its Lead Product Candidate, Opregen